Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
EBioMedicine
; 97: 104842, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37865043
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Vaccines
/
HIV Infections
/
COVID-19
Limits:
Aged
/
Humans
Language:
En
Year:
2023
Type:
Article